A Comparison of Daily and Alternate-Day Prednisolone Therapy in the Treatment of Myasthenia Gravis Myasthenia gravis
Conditions
Interventions
Sponsors
Eligibility
Inclusion criteria
Inclusion criteria: Age 18-80 years old Patients with diagnosis of myasthenia gravis at Siriraj Hospital, Mahidol University, Bangkok, Thailand Patients who have indication for corticosteroid Generalized MG or Ocular MG that not in minimal manifestation state (MMS) after taken Pyridostigmine more than 360 mg/d
Exclusion criteria
Exclusion criteria: Patients who presented with myasthenic crisis Patients who have contraindication to corticosteroids : uncontrolled infection, uncontrolled diabetes mellitus (HbA1C 9.0), severe osteoporosis (the threshold of bone density value < -2.5 SD of T-score) Patients who are currently receiving corticosteroids treatment Body weight more than 100 Kg Patients who are Anti-MuSK Ab positive Patients who are corticosteroids, Azathioprine or Mycophenolate mofetil allergy Patients who are currently pregnancy or lactation Patients who are terminally ill Patients who have active infection including TB, HBV, HCV and HIV
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| To compare side effects of alternate-day prednisolone therapy and daily prednisolone therapy for myasthenia gravis 6 months body weight, infection, number of absolute lymphocyte count, fasting blood sugar (FBS), hemoglobin A1c ( HbA1C) and lipid profile; myasthenic crisis, steroid induced-exacerbation | — |
Secondary
| Measure | Time frame |
|---|---|
| To evaluate efficacy of alternate-day prednisolone therapy compared to daily therapy for myasthenia gravis treatment by 6 months days of MMS within the first 6 months after treatment, time to MMS changes in MGFA score differentiation, QOL score, and MG composite scale | — |
Countries
Thailand
Contacts
Faculty of Medicine Siriraj Hospital